When Will a Coronavirus Vaccine Be Ready?

When Will a Coronavirus Vaccine Be Ready?

Twenty-nine vaccines in small-scale safety trials (Phase 1). According to the Oxford University scientists, of the hundreds of potential COVID-19 vaccines in development, six are in the final stages of testing, known as phase three clinical trials.

The AstraZeneca statement said information about the illness the woman suffered can not be disclosed. There are 142 vaccines in Pre-Clinical trials that are not yet in human trials.

The coronavirus vaccine could be administered via an inhaler, after Imperial College London launched a trial to test the effectiveness of delivering a candidate directly into the lungs.

AstraZeneca's vaccine uses a monkey adenovirus that shares a gene with the Covid-19 coronavirus - a platform that hasn't been subjected to any long-term studies.

The SII has said that it would resume trials "once DCGI will give us the permission to restart the trials in India".

"I think one would have to say that we're on the edge of losing control", Mark Walport, the British government's former chief scientific adviser, told BBC radio.

Oil prices add to losses as supplies swell amid weak demand
Brent oil futures were down 0.42% to $40.62 by 11:25 PM ET (4:25 AM GMT) and WTI Futures fell 0.63% to $37.8, remaining below the $40-mark.

After days of uncertainty following a safety alert in the global trials for one of the frontrunners in the Covid-19 vaccine race, AstraZeneca on Saturday said it is resuming human testing in the United Kingdom of the vaccine candidate it developed jointly with Oxford University. In fact, the vaccine-maker received a show-cause notice from the DCGI for not informing it immediately and halting the trial on the same day.

Phase III clinical trials of Russia's Sputnik V vaccine against COVID-19 will be conducted in the Brazilian states of Bahia and Parana, which has plans to produce the vaccine for Brazil and other Latin American countries.

The Oxford-AstraZeneca study had previously been stopped in July for several days after a participant developed neurological symptoms that turned out to be an undiagnosed case of multiple sclerosis that researchers said was unrelated to the vaccine.

Dr. Charlotte Summers, a lecturer in intensive care medicine at the University of Cambridge, said the pause was a sign that the Oxford team was putting safety issues first, but that it led to "much unhelpful speculation". The company is also responsible for making COVID-19 vaccine doses for a large chunk of the developing world, according to the Financial Times. "The company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic", the company said.

Italy's health minister, Roberto Speranza, welcomed the resumption of the vaccine trial, but warned that prudence was still necessary.

Related Articles